Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Mallinckrodt
McKesson
Boehringer Ingelheim
Baxter

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Gevokizumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Gevokizumab: Patents, clinical trial progress, indications

Gevokizumab is an investigational drug.

There have been 15 clinical trials for Gevokizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Uveitis, Pyoderma Gangrenosum, and Pyoderma. The leading clinical trial sponsors are XOMA (US) LLC, Institut de Recherches Internationales Servier, and Novartis Pharmaceuticals.

There are eight US patents protecting this investigational drug and fifty-two international patents.

Recent Clinical Trials for Gevokizumab
TitleSponsorPhase
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersNovartis PharmaceuticalsPhase 1
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumXOMA (US) LLCPhase 3
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease UveitisXOMA (US) LLCPhase 3

See all Gevokizumab clinical trials

Clinical Trial Summary for Gevokizumab

Top disease conditions for Gevokizumab
Top clinical trial sponsors for Gevokizumab

See all Gevokizumab clinical trials

US Patents for Gevokizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gevokizumab   Start Trial Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody The Children's Hospital of Philadelphia (Philadelphia, PA) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
Gevokizumab   Start Trial Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development TRUSTEES OF BOSTON UNIVERSITY (Boston, MA)   Start Trial
Gevokizumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Gevokizumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gevokizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Gevokizumab Canada 2946511 2034-04-21   Start Trial
Gevokizumab European Patent Office 3134120 2034-04-21   Start Trial
Gevokizumab World Intellectual Property Organization (WIPO) 2015164354 2034-04-21   Start Trial
Gevokizumab World Intellectual Property Organization (WIPO) 2018022982 2036-07-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Dow
Colorcon
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.